Photo from wikipedia
Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO‐RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO‐RAs may have… Click to show full abstract
Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO‐RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO‐RAs may have an immune modulatory role and Pizzi and colleagues provide evidence in support of this by demonstrating that TPO‐RA treatment restores the decreased regulatory T cell (Treg) numbers in the splenic microenvironment of patients with ITP.
Journal Title: British Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!